Through an agreement between the Medicines Patent Pool and ViiV Healthcare, the three generic manufacturers can develop, manufacture and supply generic versions of cabotegravir LA for PrEP in 90 countries.
Pantoprazole sodium for injection is indicated for short-term treatment of adult patients with gastroesophageal reflux disease, a history of erosive esophagitis and pathological hypersecretion.
The formulation is approved to treat seven indications, including rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn’s disease, ulcerative colitis and plaque psoriasis.
The proposed Abatacept biosimilar is a dual biologic intended to suppress neuroinflammation via multiple immunomodulatory pathways, for the treatment of neurodegenerative conditions.